Bio-Techne Corp (TECH)

Industry Biotechnology

This stock can be held in an Investment ISA and an Investment Account

Sell

$57.39

Buy

$60.42

arrow-down$-1.75 (-2.90%)

Prices updated at 12 Dec 2025, 23:53 EST

Prices minimum 15 mins delay

Prices in USD

Bio-Techne Corp and is a biotechnology company which develops, manufactures and sells biotechnology reagents, instruments and clinical diagnostic products.

NASDAQ

-1.69%

NASDAQ

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

Our Investment Fees and Charges.

Sector

Healthcare

Industry

Biotechnology

Chairman

Mr. Robert V. Baumgartner, C.P.A.

CEO

Mr. Kim Kelderman

Most recent earnings

30 Jun 2025

Fiscal year end

30 Jun 2025

Employees

3,100

Head office

614 McKinley Place N.E.

Minneapolis

United States

55413

+1 612 379-8854

-

Company website

Key personnel

Owner name chevron-l-regular chevron-r-regular	Salary
Mr. John L. Higgins Independent Director	0.10m
Dr. Joseph D. Keegan, PhD Independent Director	0.08m
Mr. Robert V. Baumgartner, C.P.A. Chairman of the Board	0.20m
Ms. Julie L. Bushman Independent Director	0.09m
Mr. James T. Hippel Principal Accounting Officer, Executive Vice President and Chief Financial Officer	0.72m
Dr. Rupert Vessey, B.M.,D.Phil.,F.R.C.P.,M.A. Independent Director	0.08m
Dr. Alpna Seth, PhD Independent Director	0.09m
Mr. Kim Kelderman Director, Chief Executive Officer and President	0.94m
Dr. Judith Klimovsky, M.D. Independent Director	0.08m
Mr. William Geist President, Protein Sciences	0.57m
Dr. Matthew McManus President, Diagnostics and Genomics Segment	0.57m
Mr. Shane Bohnen Senior Vice President, General Counsel and Corporate Secretary	0.43m
Dr. Amy Herr, PhD Independent Director	0.03m

Top 5 shareholders

Owner name chevron-l-regular chevron-r-regular	No. of shares
Vanguard Group Inc	18,438,322
BlackRock, Inc.	13,843,281
BlackRock Inc	11,887,082
T Rowe Price Associates, Inc	9,424,313
Morgan Stanley - Brokerage Accounts	7,237,878

Director dealings

Date chevron-l-regular chevron-r-regular	Action
01 Nov 2024	-
01 Nov 2024	-
01 Nov 2024	-
01 Nov 2024	-
01 Nov 2024	-
01 Nov 2024	-
01 Nov 2024	-
01 Nov 2024	-
24 Oct 2024	-
24 Oct 2024	-
24 Oct 2024	-
24 Oct 2024	-
24 Oct 2024	-
24 Oct 2024	-
24 Oct 2024	-
24 Oct 2024	-
24 Oct 2024	-
24 Oct 2024	-
24 Oct 2024	-
24 Oct 2024	-

Please note that past performance is not a reliable indicator of future returns.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.